Citi lowered the firm’s price target on Bausch + Lomb (BLCO) to C$19 from C$21 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating
- Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c
- Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B
- Bausch + Lomb announces narrative review on certain B vitamins
- Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled